Research Article

Neuroprotection against Amyloid-β-Induced DNA Double-Strand Breaks Is Mediated by Multiple Retinoic Acid-Dependent Pathways

Julien Colas(1), Natacha Chessel(1), Allaeddine Ouared(1), Emmanuelle Gruz-Gibelli(1), Pascale Marin(1), François R. Herrmann(2), and Armand Savioz(1,3)

1Department of Psychiatry, Division of Geriatric Psychiatry, University Hospital of Geneva, Geneva, Switzerland
2Department of Rehabilitation and Geriatrics, Division of Geriatrics, University Hospital of Geneva and University of Geneva, Geneva, Switzerland
3Geneva University Neurocenter, University of Geneva, Geneva, Switzerland

Correspondence should be addressed to Julien Colas; jul.colas92160@gmail.com, Natacha Chessel; natacha.chessel@gmail.com, and Armand Savioz; armand.savioz@hcuge.ch

Received 3 December 2019; Revised 30 January 2020; Accepted 28 February 2020; Published 20 March 2020

1. Introduction

Recently, there was an increased interest in the involvement of cell nuclear changes in Alzheimer’s disease (AD) as most of its key players have been shown to be involved either in gene expression, e.g., ApoE4 [1], or in DNA alterations, e.g., the Tau protein [2]. It has been shown that the Aβ1-42 peptide—in this paper referred to as Aβ peptide—not only regulates gene transcription [3, 4] but also impairs DNA repair [5]. Furthermore, the Aβ peptide generates DNA double-strand breaks or DSBs [6, 7] through oxidative stress [8], through depletion of the DNA repair factor BRCA1 [9], and through activity reduction of the DNA-dependent protein kinase (DNA-PK) [10, 11], a key enzyme of the nonhomologous end joining pathway (NHEJ) involved in DSB repair in neurons [12]. In this context, it is worth knowing that DSBs within promoter regions have been shown to be needed for transcription of neuronal early-response genes [13] or to play a role in gene silencing [14]. DSBs are involved in physiological processes, such as in memorisation [6], in aging [15–17], and in AD [16, 18–23].
Several factors playing a role against DNA damages have been identified, such as glutamine against etoposide-induced damages [24] or histones against DNA oxidation [8]. Some of them are known in relation to AD. Thus, monomeric Tau can protect DNA against heat shock-induced damages [25, 26] and NAD against Aβ-induced damages [7]. Recently, we showed in astrocytic DI TNC1 and neuroblastoma SH-SY5Y cell lines, as well as in the murine neocortex, that the vitamin A derivative all-trans-retinoic acid (RA) and the RARα/β agonist Am80 are involved in the repair of Aβ-induced DSBs [27], RA or Am80 being added after Aβ in these experiments. The DNA-dependent protein kinase (DNA-PK) of the NHEJ pathway and Ataxia Telangiectasia Mutated kinase (ATM) were shown to be implicated as repair factors [27]. This represents an additional effect of RA besides the already known ones as a neuroprotective agent for Alzheimer’s disease [28–31].

RA does not only repair Aβ-induced DSBs but also decreases the Aβ peptide production from the Amyloid Precursor Protein or APP. Indeed, RA can increase, via the RAR receptor, the expression of ADAM10 (a disintegrin and metalloproteinase domain-containing protein 10), the major a-secretase [32], more than it increases the β-site cleaving enzyme BACE1, a β-secretase [33]. Furthermore, RA achieves a similar result by inhibiting the γ-secretase (or Presenilin-1) activity through activation of the Extracellular Signal-Regulated Kinase (ERK) 1/2 [34]. Thus, by changing the expression of enzymes of the amyloid cascade, RA might also prevent the formation of Aβ-induced DSBs and be a factor of neuroprotection against Aβ-induced DSBs and not just of DSB repair. The aim of the present study was to demonstrate that indeed RA not only repairs Aβ-induced DSBs, as described in our previous publication [27], but also prevents their occurrence. For such a purpose, neuroprotective experiments have been carried out with RA added before or at the same time as Aβ and not after as in repair experiments.

Overall, we propose that RA can protect DNA against Aβ-induced DSBs potentially allowing prevention strategies. We also show that it can protect posttranscriptionally through both the RARα/β/γ and PPARβ/δ receptor-dependent pathways [35, 36] and in part via PPARβ/δ-RXR heterodimerization.

2. Materials and Methods

2.1. Murine Brain Tissues and Dissections. One- to 4- and 16- to 17-month-old C57BL/6J male mice (Janvier, Le Genest-St-Isle, France) were sacrificed by CO2 inhalation, and their brains were isolated. Either all cortical layers or the superficial (1–III) and deep (V–VI) neocortical layers, separated under a binocular microscope at the level of layer IV, were used. In all cases, the most rostral and caudal cortical parts were excluded. These tissues, as well as the hippocampus, were dissected in PBS and minced. The treatments with 5 μM RA (Sigma-Aldrich), 20 μM monomeric Aβ1-42 peptides (Enzo Life Sciences), and RA+ Aβ were immediately carried out in a neurobasal medium (Gibco Life Technologies) in the presence of Penicillin G (100 IU/mL)/Streptomycin (100 μg/mL; Invitrogen) and 2 mM L-glutamine (Gibco Life Technologies) for 30 min at 37°C in a CO2 incubator containing 5% CO2 and 95% humidified air. After a centrifugation step (300 rpm, 3 min), the supernatant was discarded, the pellet was mixed mechanically in PBS in the presence of 2 mM EDTA, and the cells counted for the comet and the cell viability assays.

For each treatment condition, three mice were sacrificed in accordance with Federal Swiss Veterinary regulations and institutional approval.

2.2. Cell Culture. SH-SY5Y cells (European Collection of Animal Cell Culture, UK) were grown in a CO2 incubator at 37°C in RPMI-1640 (Gibco Life Technologies) with 10% FCS (Bioconcept, Switzerland), Penicillin/Streptomycin, and L-glutamine. Once at confluence, cells were released in DPBS (150 mM NaCl, 3 mM KCl, 1.5 mM KH2PO4, 7.9 mM Na2HPO4, 2H2O, 0.1 mM EDTA, pH 7.4), centrifuged 5 min at 1000 rpm, and resuspended at the desired dilution in RPMI-1640 with 10% FCS.

DMEM (Sigma) supplemented with 10% FCS was used to grow the DI TNC1 astrocytic cells [37, 38]. Once at confluence, they were released in trypsin solution (0.25%), centrifuged 5 min at 1100 rpm, and resuspended at the desired dilution in DMEM with 10% FCS.

2.3. Cell Treatments. For the cell treatments, the 10% FCS medium was replaced two days before the experiment by the 1% FCS medium. Cultured cells were treated or not, in a 37°C incubator containing 5% CO2 and 95% humidified air for 30 min with 1 μM RA, for the Western blots, to 5 μM RA, then after medium change, for further 30 min with 20 μM Aβ peptides or not (ø) resulting in four combinations of 2 × 30 min treatments (ø–ø, ø–Aβ, RA–ø, and RA–Aβ). Treatments were also carried out simultaneously, and RA replaced by 5 μM 9-cis RA (Sigma-Aldrich), 1 μM glutathione (Sigma-Aldrich), 1 μM α-tocopherol, 100 μM carnosine (Sigma-Aldrich), or 100 μM vitamin C (Sigma-Aldrich). Furthermore, 1 μg/mL transcription inhibitor actinomycin D (Sigma-Aldrich), 35 μM translation inhibitor cycloheximide (CHX; Sigma-Aldrich), 50 μM RARα/β/γ antagonist AGN 193109 (Abcam), and 10 μM PPARβ/δ antagonist GSK 3787 (Santa Cruz Biotechnology) were added or not, in combination with RA and/or Aβ for 30 min.

2.4. Neutral Single-Cell Gel Electrophoresis (Comet Assay). The Trevigen Comet Assay™ kit (AMS Biotechnology, UK) was used with SH-SY5Y or DI TNC1 cells, and the homogenized cortical tissues with the following modifications. Subsequently to the treatments, 1.0 to 1.5 × 105 cells/mL were resuspended in ice-cold Ca2+- and Mg2+-free PBS. For the dissociated tissue, 20 mM EDTA was added to an equivalent number of cells in ice-cold Ca2+- and Mg2+-free PBS and processed as the cultured cells. 50 μL of the mixture was immediately added to a comet slide (AMS Biotechnology), put in the dark at 4°C for 10 min to promote agarose gelling and then at 4°C for 60 min in prechilled lysis solution (AMS Biotechnology). DSBs were separated by electrophoresis for 45 min at 26 V following an incubation step of the slides in
Neutral Electrophoresis Buffer (100 mM Tris base, 0.3 M sodium acetate, pH 9.0) at 4°C for 30 min. The slides were subsequently immersed in 70% ethanol at room temperature for 30 min and air dried. DNA was stained with 100 μL SYBR Green I dye (Gibco Life Technologies) diluted 1:1000 in water for 10 min and then rinsed with distilled water, all at room temperature. Generally, at least 30 comets per treatments were photographed with an Olympus digital camera attached to an epifluorescent Zeiss Axioplan microscope (Axio vision rel 4.6). The length of one comet was obtained by subtracting the diameter of the cell body (perpendicular to the orientation of the electrophoresis) from the total signal length (parallel to the orientation of the electrophoresis) consisting of the length of the cell body and of the comet tail. This value was then converted in μm according to the magnification factor of the microscope.

2.5. Western Blot. For the Western blots, the dissected tissue was weighted, homogenized, and treated during different times in the neurobasal medium with Penicillin/Streptomycin and L-glutamine. After a centrifugation step at 1200 rpm for 5 min, the supernatant was discarded and 600 μL of lysis buffer 1x (50 mM Tris, 2% SDS, 5 mM EDTA, and 2 mM EGTA, pH 6.8) per 20 mg tissue, 125 nM okadaic acid, and protease inhibitor cocktail diluted 1:100 (Sigma) were added. Each sample was finally sonicated. The protein concentrations were quantified by the BCA protein assay (Pierce, Thermo Scientific), and 20 μg of proteins were diluted in Laemmli loading buffer (20 mM Tris-HCl, pH 6.8, 1% SDS, 7% glycerol, 2% β-mercaptoethanol, 0.05% bromophenol blue), denatured (100°C, 5 min), separated (Mini-PROTEAN TGX precast gels, Bio-Rad, 60 V, 200 rpm for 5 min, the supernatant was discarded and 2 mM EGTA, pH 6.8) per 20 mg tissue, 125 nM okadaic acid, and protease inhibitor cocktail diluted 1:100 (Sigma) were added. The following primary rabbit polyclonal antibodies were used: anti-ADAM10 (ab1997, Abcam); anti-APP, C-terminal (AICD, A8717, Sigma-Aldrich); anti-BACE1 (#5606, Cell Signalling Technology); anti-GluN2B (NR2B; ab65783, Abcam); anti-Peroxisome Proliferator-Activated Receptor β/δ (PPARβ/δ, H-74, sc-7197, Santa Cruz Biotechnology); anti-Presenilin-1 (H-70, sc-7860, Santa Cruz Biotechnology); anti-PSD95 (PA1-4667, Thermo Fisher Scientific); and anti-RARα (PA1-810A, Thermo Fisher Scientific). The following primary mouse monoclonal antibodies were used: AT8 (MN1020, Thermo Fisher Scientific) and Tau1 (MAB3420, Millipore). All primary antibodies were diluted 1:1000 except when specified otherwise. The horseradish peroxidase-labeled anti-rabbit or anti-mouse antibodies (DakoCytomation) were diluted 1:3000 in PBS with 0.2% Tween 20, 0.5% BSA, and 5% milk and used as secondary antibodies.

The Amersham ECL™ Western Blotting Detection Reagent (GE Healthcare, Buckinghamshire, UK) on Hyperfilm ECL (Amersham Biosciences, GE Healthcare) was used to detect specific signals. Mouse monoclonal anti-GAPDH (Millipore; 1:10000) was used to verify equal protein loading as well as DB71 protein staining of the blotting membranes (Aldrich, Milwaukee, USA). The ratios of the signals for a defined protein, measured by densitometry (U:Genius 3 with GeneTools from Syngene) and divided by the DB71 or GAPDH signals, were used for statistical analysis.

2.6. Immunocytochemistry. After removal of the cell medium, SH-SY5Y cells were treated or not with 5 μM RA for 10 and then for 20 min with 20 μM Aβ or not, rinsed 5 min in PBS, fixed 30 min in 4% paraformaldehyde, and finally washed again 5 min in PBS. After 10 min permeabilisation in PBS in the presence of 0.2% Triton X-100, the cells were washed twice as above and incubated 90-120 min at room temperature in PBS with the primary antibody against PPARβ/δ (H-74, sc-7197, Santa Cruz Biotechnology, 1:50) and the one against RXRα/β/γ (C-20, sc-831, Santa Cruz Biotechnology, 1:25), or the antibody against RARα/β/γ (sc-366090, Santa Cruz Biotechnology, 1:100) and the one against RXRα/β/γ. The cells were then washed twice, incubated 1 h at room temperature with the secondary fluorescent anti-goat or anti-rabbit antibodies (Alexa, 1:1000), rinsed again 5 min in PBS, colored 5 min in 0.1% DAPI, and finally mounted in fluorosave. Omission of the primary antibodies resulted in no immunopositive signal over background. Analyses were carried out with an epifluorescent Zeiss Axio-plan microscope.

2.7. Duolink™ In Situ Proximity Ligation Assay (PLA). Cells were treated or not with 5 μM RA for 10, 30, or 60 min and then for, respectively, 20, 30, or 60 min with 20 μM Aβ or not. They were subsequently deposited on glass slides previously sterilized with alcohol 100%. They were fixed in PAF 4% during 20 min, washed in 1x Duolink in situ Wash Buffer A (Sigma), and incubated in a drop of Duolink blocking solution for 30 min. Then, the primary antibody anti-RARα (PA1-810A, Thermo Fisher Scientific) or anti-PPARβ/δ (H-74, sc-7197, Santa Cruz Biotechnology) was pooled with anti-RXRα/β/γ (C-20, sc-831, Santa Cruz Biotechnology) after having been diluted in Antibody Diluent (Sigma). Both antibodies were incubated 1 h and 30 min at room temperature. Subsequently, the cells were washed with PBS 1x (1 mL/well). The two PLA probes, in situ PLA Probe anti-rabbit Plus and in situ PLA Probe anti-mouse Minus, diluted 1:5 in 80 μL primary antibody solution and kept for 20 min at room temperature, were added. The samples were incubated in a preheated humidity chamber for 1 h at 37°C. They were washed with 1x Wash Buffer A for 2 × 5 min under gentle agitation and 80 μL ligation solution diluted 1:40 (1 U/μL) were added and incubated for 30 min at 37°C. After removal of the ligation solution, the cells were washed as before in the Wash Buffer A but for 2 × 1 min, and the polymerase (10 units/μL) was diluted 1:80 in the amplification solution, added, and incubated in a preheated humidity chamber for 100 min at 37°C. Afterwards, the solution was removed and the cells washed with 1x Wash Buffer B (Sigma) for 2 × 2 min and subsequently with 0.01x Wash Buffer B for 1 min. Then, the slides were dried at room temperature in the dark, mounted with a minimal volume of FluorSave.
(Calbiochem) with DAPI (1/5000), and, after 5 min, analysed with an epifluorescent Zeiss Axioplan microscope.

2.8. Statistical Analysis. Values of mean comet tail length were compared for each experiment by a one-way analysis of variance (ANOVA). When overall statistically significant treatment differences were reached by ANOVA, comparisons of means among the subgroups were calculated with Bonferroni corrections. In parallel, the nonparametric Kruskal-Wallis test was used to compare the shape of comet tail distribution also with Bonferroni corrections to compare subgroups. For the Western blots, gene expression was compared using two-way repeated measures ANOVA, with age (young versus old) and treatment effect (without RA and 0.5 h, 1 h, 2 h, and 3 h with RA) along with their interaction. Treatment was the within-subject factor. The same analysis was performed separately for measures of the superficial and deep cortical layers, for each protein (e.g., PSD 95, NR2B) normalized with the control used (DB71 or GAPDH). The significance of values was determined using the Greenhouse–Geisser method. The level of significance is $p < 0.05$. Analyses were carried out with the Stata 14.1 software (Stat Corp., TX, USA, 2013). Alternatively, we used the program Prism 7 (GraphPad).

3. Results

3.1. Retinoic Acid Protects against Aβ-Induced DSBs in SH-SY5Y and DI TNC1 Cells as well as in the Neocortex of Young and Aged C57BL/6J Mice. To demonstrate that RA can protect against Aβ-induced DSBs, SH-SY5Y cells and astrocytic DI TNC1 cells were treated with RA half an hour before the addition of Aβ or not, for 30 min. The presence of RA before Aβ induced in comets with mean tail lengths similar to untreated lysed or RA-treated SH-SY5Y or DI TNC1 cells and significantly shorter than Aβ-treated cells (Figures 1(a), 1(b), 1(e), and 1(f)). We observed a slightly more important decrease of mean comet tail length in astrocytic DI TNC1 cells (48%) than in SH-SY5Y cells (32%) for the RA neuroprotective treatment against Aβ (average of 3 experiments).

RA added half an hour before the Aβ treatment can protect also against DSBs in cortical tissues originating from young (4 months old; $n = 3$) and aged (16 months old; $n = 3$) C57BL/6J male mice. The resulting tail lengths were comparable in length to the untreated lysed cortical cells and to the cortical cells treated with RA alone (Figures 1(c) and 1(d)). The mean comet tail length was significantly higher in Aβ-treated cortical cells compared to all other conditions in the young as well as in the aged mice (Figures 1(g) and 1(h)). The difference in mean comet tail lengths between the Aβ treatment and other conditions (no treatment or RA treatment alone) was less important in the aged compared to the young mice, possibly due to the decreased metabolism. However, the difference between the treatments of Aβ and RA-Aβ was statistically significant in all 3 young as well as in all 3 aged mice. We observed a more important decrease of mean comet tail length in young mice (45%) than in aged mice (25%) for the RA neuroprotective treatment against Aβ (average of 3 experiments). There was also a global effect of age ($p = 0.005$) for all conditions grouped together in favor of a decrease of DSBs with age. Note that RA protects specifically against Aβ-induced DSBs. Indeed, SH-SY5Y cells grown in 10% FCS and treated with 100 nM etoposide for 24 h showed a significant increase of DSBs ($p < 0.001, n = 35$) that was not reduced significantly by the presence of 1 μM RA, contrary to the significant increase of DSBs with 4 μM Aβ for 24 h that was significantly decreased by the addition of RA ($p < 0.001, n = 35$; results not shown).

3.2. Neuroprotective Effect of Retinoic Acid against Aβ-Induced DSBs in SH-SY5Y Cells in comparison to Other Antioxidants. SH-SY5Y cells were treated with glutathione, α-tocopherol, L-carnosine, or vitamin C and/or Aβ for 1 h in comparison to the RA treatments (Figure 2). If there was a significant decrease ($p < 0.05$; Bonferroni test) in average tail lengths comparing the Aβ treatment with the Aβ+RA or Aβ+glutathione treatments, there was no significant difference between RA or glutathione and no treatment. Furthermore, no additive or synergistic effects were observed by comparing the Aβ+RA or the Aβ+glutathione treatments with the Aβ+RA+glutathione treatment (Figures 2(a) and 2(b)). Similar observations were made with α-tocopherol (Figure 2(c)) and L-carnosine (Figure 2(d)), i.e., there were no differences between the treatments with these antioxidants and no treatment and no additive or synergistic effects. Vitamin C was able to reduce DSBs more than RA in the absence of Aβ in two-thirds of the experiments. However, if vitamin C significantly ($p < 0.05$) reduced DSBs compared to the controls, the Aβ-induced DSBs in the presence of vitamin C were always significantly more numerous than in the presence of RA, indicating that vitamin C was less efficient to reduce Aβ-induced DSBs than RA. Furthermore, combined treatment of vitamin C and RA showed no diminution of DSBs compared to the untreated cells (Figure 2(e)).

3.3. Retinoic Acid-Dependent Protein Expression in Cortical Regions of Young and Aged C57BL/6J Mice in relation to the Amyloid Cascade. The effect of 1 μM RA on the expression of various gene products was tested in three 1-month-old male versus three 17-month-old male C57BL/6J mice in the dissected deep and superficial neocortical layers and the hippocampus (Figure 3). The gene products belonged either to the amyloid cascade (Presenilin-1/γ-secretase or PS1, BACE1/β-secretase, ADAM10/α-secretase (immature form), and APP (C-terminus)), to Tau (AT8, Tau1), to synaptic markers (PSD95, GluN2B), or to receptors of the RA pathways, RARα and PPARβ/δ. Their expressions were always measured in comparison to the controls, GAPDH or DB71 protein staining. Statistical analyses were carried out only for the neocortex and not the hippocampus, this structure being less homogenous than the neocortex. However, the results appeared to be similar. Whereas PS1 and BACE1 were not increased after 1 h RA treatment, ADAM10 and APP were increased by factors 5.5 and 1.3 in the deep cortical layers and 1.2 and 1.05 in the superficial cortical layers in young and aged mice grouped together. Significance
Wilcoxon signed-ranked test; $p = 0.0277$) was however only reached in the deep cortical layers with ADAM10 and APP. ADAM10 and APP increased in both cortical layers with age ($p = 0.0495$; two-sample Wilcoxon rank-sum (Mann-Whitney)), whereas PS1 and BACE1 diminished in both layers with age ($p = 0.0495$). These data suggest that RA decreases the amyloid cascade and the $A\beta$ production in young and in aged mice.

**Figure 1:** All-trans-retinoic acid (RA) protects against $A\beta$-induced DSBs in SH-SY5Y and astrocytic DI TNC$_1$ cells as well as in the neocortex of young and aged male C57BL/6J mice. Representative pictures of comets with various tail lengths of (a) SH-SY5Y cells, of (b) DI TNC$_1$ cells, and of cortical tissues originating from (c) young (4 months; $n = 3$ mice) or (d) aged (16 months; $n = 3$) mice following RA (5 $\mu$M) and/or $A\beta$ (20 $\mu$M) in vitro treatments for $2 \times 30$ min (SH-SY5Y cells; cortical tissue) and $2 \times 1$ h (DI TNC$_1$ cells). ø = without treatment; scale bar: 200 $\mu$M. Box plots of mean comet tail lengths of (e) SH-SY5Y cells (number of cells measured: $33 < n < 52$), of (f) DI TNC$_1$ cells ($55 < n < 72$), of (g) 3 young ($30 < n < 55$), and of (h) 3 aged mice ($31 < n < 57$). ANOVA with Bonferroni correction: one experiment for SH-SY5Y cells (replicated in Figure 4(e)) and 3 for DI TNC$_1$ cells; * $p < 0.05$ for all experiments or all three mice; † $p < 0.05$ for 2 out of 3 mice; ‡ $p < 0.05$ for 1 out of 3 mice.
Concerning the phosphorylated Tau isoforms, the main band observed with AT8 (around 60 kDa) increased after 1 h RA treatment by factors 10 and 2.2 in the young mice and 8.7 and 3.6 in the old mice for the deep and superficial cortical layers, respectively. Thus, statistical analyses showed an increase due to the RA treatment in the deep layers \((p = 0.0214)\) when normalized with GAPDH (not DB71) but not in the superficial layers. The main band of

**Figure 2:** Effects of antioxidants against Aβ-induced \((20 \mu M)\) DSBs in SH-SY5Y cells compared to all-trans-retinoic acid (RA; \(5 \mu M\)) treatment. In (a), example of comet assay with 1 h treatments with Aβ, RA, and/or glutathione (glut). Scale bar: 200 \(\mu M\). In (b) to (e), data analyses: (b) glutathione (1 \(\mu M\)), (c) \(\alpha\)-tocopherol (toco; 1 \(\mu M\)), (d) L-carnosine (carn; 100 \(\mu M\)), and (e) vitamin C (vitC; 100 \(\mu M\)). Box plots of mean comet tail lengths (number of cells measured: \(18 < n < 53\)). ANOVA with Bonferroni correction: the experiments with L-carnosine and vitamin C were repeated 3 times \((\circ p < 0.05 \text{ for 1 experiment out of 3}; \ast p < 0.05 \text{ for 2 experiments out of 3}; \ast\ast p < 0.05 \text{ for 3 experiments out of 3})\) whereas the experiments with glutathione and \(\alpha\)-tocopherol were carried out 1 time \((\# p < 0.05).\) φ = without treatment.
unphosphorylated Tau, around 60 kDa, detected with the Tau1 antibody, increased after 1 h RA treatment by factors 1.1 and 1.1 in the young mice and 1.5 and 1.3 in the old mice for the deep and superficial cortical layers, respectively. Statistical analyses did not show a significant increase following the RA treatment, whereas a band of 70 kDa (\( p = 0.043 \)) was detected in both young and old mice. Protein sizes are indicated on the right. A size range is given for Tau isoforms (AT8 and Tau1).

This observation appears to be corroborated by an increase of postsynaptic proteins PSD95 and GluN2B after 1 h RA treatment in young mice and less so in old mice in all tissues, despite the fact that a statistically significant difference in relation either to the treatment or to age was not reached.

Finally, the RAR\( \alpha \) and PPAR\( \beta/\delta \) receptors showed no changes in expression following the RA treatment independently of age, if we except a significant increase of the PPAR\( \beta/\delta \) receptor in the deep layers after 1 h treatment with RA (\( p = 0.043 \)). There was a significant increase of PPAR\( \beta/\delta \) and RAR\( \alpha \) receptors in old mice compared to young ones in the superficial and the deep cortical layers for no or 1 h treatment with RA and most of the time for 2 h treatment. Finally, both PPAR\( \beta/\delta \) and RAR\( \alpha \) receptors were statistically more expressed in the superficial layers than the deep layers of the neocortex.

Overall, the significant increase of proteins ADAM10, APP, and phosphorylated and unphosphorylated Tau proteins, not of PS1 and BACE1, especially in the deep cortical layers, suggests an imbalance in favor of the antiamyloidogenic pathway following the RA treatment. This appears not to be due to an increase in expression of the RAR\( \alpha \) and PPAR\( \beta/\delta \) proteins subsequently to the RA treatment, except in the deep layers for PPAR\( \beta/\delta \). However, a higher expression of these receptors with age and in the superficial cortical layers might play a neuroprotective role.

### 3.4. A\( \beta \)-Induced DSBs Are Transcription and Translation Dependent, Contrary to RA Protection against DSBs.

The next step was to investigate whether both RA-dependent pathways (Figure 4(a)) needed transcription or translation.
Figure 4: (a) Schematic representation of the RA and 9-cis RA receptors, RAR, PPAR, and RXR, and their antagonists, AGN 193109 (AGN) for RARα,β,γ and GSK 3787 (GSK) for PPARβ/δ, as well as their neuroprotective effect on Aβ-induced double-strand breaks (DSBs). (b) Effects of 5 μM all-trans-retinoic acid (RA) against Aβ-induced DSBs and of 20 μM Aβ on DSB production in the presence of the transcription inhibitor actinomycin D (Acti; 1 μg/mL) and of the translation inhibitor cycloheximide (CHX; 10 μg/mL) in SH-SY5Y cells after a 1 h treatment. The inhibitors do not interfere significantly with the effect of RA whereas they do with Aβ. Box plots of mean comet tail lengths of SH-SY5Y cells (number of cells measured: 27 < n < 50). ANOVA with Bonferroni correction: the experiment was repeated 3 times (*p < 0.05 for 1 experiment out of 3; **p < 0.05 for 2 experiments out of 3; ***p < 0.05 for 3 experiments out of 3). (c) Box plots of mean comet tail lengths of SH-SY5Y cells (31 < n < 53) following a 1 h treatment with RA, 9-cis RA (5 μM), and/or Aβ in the presence of AGN (50 μM) or not. (d) Box plots of mean comet tail lengths of SH-SY5Y cells (36 < n < 50) following a 30 min treatment with Aβ, RA, AGN, and GSK (10⁻⁸ M) and a combination of these factors. (e) Box plots of mean comet tail lengths of SH-SY5Y cells (31 < n < 34) following a 30 min treatment with RA, AGN, and/or GSK, and after a washing step, a second 30 min treatment with Aβ or not. (c–e) ANOVA with Bonferroni correction: *p < 0.05. ø = without treatment.
(Figure 4(b)) or which one was preventing Aβ-induced DSBs (Figures 4(c)–4(e)). To verify if the effect of RA and Aβ on DSB protection and production, respectively, involves transcription or translation, a comet assay was carried out in triplicate with SH-SY5Y cells. They were treated 1 h with RA (5 μM), Aβ (20 μM), and RA+Aβ in the presence of transcription inhibitor, actinomycin (1 μg/mL), or of translation inhibitor, cycloheximide (10 μg/mL; Figure 4(b)). No difference in DSB levels was observed between the untreated and the actinomycin- or cycloheximide-treated cells, showing that the physiological background of DSBs is transcription- and translation-independent. There was a statistical decrease in Aβ-induced DSBs comparing Aβ and Aβ+actinomycin, or Aβ and Aβ+cycloheximide, indicating that Aβ needs transcription and translation for DSB production. On the contrary, no statistically differences in DSBs were detected between RA and RA+cycloheximide or between RA and RA+actinomycin. This indicates that, at least for a 1 h treatment, DSB levels due to RA are transcription- and translation-independent and that RA can protect against Aβ-induced DSBs at the posttranslational level.

The time needed for inhibiting transcription and/or translation seems however important. Indeed, in an experiment with a 30 min treatment only (results not shown), we observed a significant increase of DSBs with Aβ, whereas, for all the other conditions (e.g., Aβ+cycloheximide or Aβ+actinomycin), the average DSB values were lower, but not significant. The differences between RA and RA+cycloheximide or between RA and RA+actinomycin were not significant, corroborating the observation that DSB levels due to short-term RA treatments are transcription- and translation-independent.

3.5. RA Neuroprotection against Aβ-Induced DSBs Involves Both the RARα/β/δ and PPARα/β/δ Pathways. To determine which RA-dependent pathways were involved in protection against Aβ-induced DSBs, we first tried to inhibit the RA-mediated neuroprotective effect against Aβ-induced DSBs with the RARα/β/γ antagonist AGN 193109 (or AGN) in the presence or not of the 9-cis RA that binds not only to RARs but also to RXRs (Figure 4(a)). For this purpose, SH-SY5Y cells were treated for 30 min with 5 μM RA or 9-cis RA, and/or 20 μM Aβ, in the presence or not of AGN. If there was a significant decrease (p < 0.05; Bonferroni test) of average tail lengths comparing the RA+Aβ or 9-cis RA+Aβ treatments with the Aβ treatment, no significant difference was observed between both retinoids in the presence of Aβ. RA and 9-cis RA showed no additive or synergistic effects (Figure 4(c)). The presence of AGN was unable to prevent the neuroprotective effect of either RA or 9-cis RA, suggesting the involvement of at least another independent neuroprotective pathway. We decided to investigate the PPAR pathway (Figure 4(d)) by inhibiting PPAR, RAR, or both receptors together, in the absence or presence of RA or RA+Aβ, with AGN and/or the PPARβ/δ antagonist GSK 3787 (or GSK). We showed first that SH-SY5Y cell viability was not altered by GSK compared to the untreated control when the concentrations were between 10⁻⁵ and 10⁻⁹ M for a treatment of 30 min. However, a higher concentration (10⁻³ M) caused an important decrease of viability similar to that of digitonin (results not shown). Thus, the concentration of 10⁻³ M GSK was chosen, as it does not alter cell viability. The experiment in Figure 4(d) with 30 min treatment revealed that both pathways, the RAR and the PPAR pathways, contribute to the neuroprotective effect of RA against Aβ-induced DSBs (Aβ+RA versus Aβ+RA+AGN or Aβ+RA+GSK). Only when both pathways were inhibited together was RA unable to protect against Aβ-induced DSBs (RA+AGN+GSK versus Aβ+RA+AGN+GSK). Furthermore, both pathways appear to be active in the absence of exogenously added RA, as a significant increase was observed between the AGN or the GSK treatment and the RA treatment.

This experience was repeated but with two steps for 30 min each(Figure 4(e)). The neuroprotection step—RA, AGN, GSK, RA+AGN, RA+GSK, RA+AGN+GSK, or no treatment—inhibited or not, was, subsequently to a washing step, followed by the addition of Aβ, or not, as control. The observations showed that, as the inhibition of PPAR by GSK in the presence of RA and Aβ significantly decreased DSBs in comparison to RA-Aβ, the RAR pathway plays a major role under these experimental conditions. As no difference was observed between the treatment with AGN in the presence of RA and Aβ, and the combined RA-Aβ treatment, this also suggests that the PPAR pathway plays a role in neuroprotection against RA. The fact that the RA+GSK-Aβ treatment was significantly different compared to the ⪈Aβ treatment, but not to the RA+AGN-Aβ treatment, suggests however that the PPAR pathway is less important under these circumstances. However, when both pathways were inhibited together (RA+AGN+GSK-5Aβ), neuroprotection appeared almost fully inhibited. Overall, experiments of Figures 4(d) and 4(e) showed similar results, i.e., both, the RAR and PPAR pathways, are involved in prevention against Aβ-induced DSBs and complement each other.

3.6. Activation of PPAR-RXR Heterodimerization following RA–Aβ Neuroprotective Treatment. With both PPAR and RAR pathways being involved in neuroprotection against DSBs, we tried next to show their activation by immunofluorescent cytochemistry and by Duolink™ in situ proximity ligation assay (PLA) using in both cases the same treatments. These methods were carried out to determine either colocalisation or heterodimerization of PPARβ/δ and RXRa/β/γ or RARα and RXRa/β/γ.

By immunocytochemistry (Figure 5(a)), we could observe in SH-SY5Y cells low RXRa/β/γ signals and increased PPARβ/δ signals in the cytoplasm, not in the cell nucleus, especially when they were treated with RA and Aβ. Moreover, colocalisation of PPAR and RXR signals could be found in the cytoplasm, notably when the cells were treated with RA and Aβ, suggesting possible PPAR-RXR interactions in agreement with PLA results. In the PLA experiments, when the SH-SY5Y cells were treated simultaneously with Aβ and RA for 30 min, no significant increases of PPAR-RXR or RAR-RXR heterodimers occurred either in the cell nucleus or the cytoplasm. However, a nonsignificant (p = 0.07) increased number of PPAR-RXR signals was...
Figure 5: Neuroprotection experiments carried out with SH-SY5Y cells to show the activation of RA-dependent pathways by a 10 min RA treatment or not (ø), followed by a 20 min treatment with Aβ or not (ø10⁰–ø20⁰, ø10⁰–Aβ20⁰, RA10⁰–ø20⁰, and RA10⁰–Aβ20⁰). (a) By immunofluorescent cytochemistry, it was shown that PPARβ/δ (green) increased in the cytoplasm with the RA–Aβ treatment, whereas a cytoplasmic increase of the RXRα/β/γ (red) could not be observed. However, sites of colocalisation (white arrows, green-yellow signals) could be detected (Merge, PPAR-RXR, or all channels). Signals were too faint in the cell nucleus (DAPI). (b) Duolink™ proximity ligation assay was used to determine PPARβ/δ and RXRα/β/γ heterodimerization under the same conditions as in (a). A significant increase of PPAR-RXR signals was observed with the RA–Aβ treatment only in the cytoplasm when compared to the ø–ø (p = 0.0125) or ø–Aβ (p = 0.0145) treatments. Only a nonsignificant (ns) increase was observed in the cell nuclei. The number of pictures analysed is 6 to 9. Similar experiments for RARα and RXRα/β/γ resulted in no significant differences. Scale bar for (a): 25 μM and for (b): 13 μM.
observed with the RA and Aβ treatment compared to the nontreated cells in the cytoplasm but not in the nucleus. When we repeated the experiment with a 10 min neuroprotective step (RA or ø) followed by a 20 min Aβ treatment or not (ø-ø, ø-Aβ, RA-ø, and RA-Aβ), we detected a significant increase of PPAR-RXR signals (Figure 5(b)), not of RAR-RXR signals (results not shown), with the RA–Aβ treatment only compared to the ø-ø (p = 0.0125) or ø-Aβ (p = 0.0145) treatments in the cytoplasm. An increase was observed in the cell nucleus; however, it was not significant. The immunocytochemical and the PLA results both support enhanced interactions of PPAR-RXR within the chosen time range. This was not the case for the RAR-RXR data (results not shown). Overall, this suggests that in the presence of RA and Aβ, not of RA or Aβ alone, PPAR-RXR interactions are favored thus decreasing DSBs.

4. Discussion

4.1. Retinoic Acid Protects against Aβ-Induced DSBs. In 17 experiments, we showed that 20 μM Aβ42 produced in average 101 μm long comet tails, whereas no treatment, 5 μM RA, Aβ42 added together with RA, and control without lysis generated mean tail lengths of 74.8, 70.2, 73.2, and 0.4 μm, respectively. This clearly illustrates the effect of Aβ on DSB production and of the counteracting effect of RA, i.e., an effect that can either be reparative (RA added after Aβ) or protective (RA added at the same time or before Aβ). Whereas in a previous publication we demonstrated that RA can repair Aβ-induced DSBs [27], in the present work, we showed that RA also prevents Aβ-induced DSBs. RA can do it not only in SH-SY5Y and astrocytic DI TNC, cells but also in the neocortex of young and aged C57BL/6 mice.

4.2. Neuroprotection against Aβ-Induced DSBs Is Mediated by Multiple Metabolic Pathways beside the RA-Dependent Pathways. All compounds studied beside RA, i.e., glutathione, α-tocopherol, L-carnitine, and vitamin C, were also able to decrease the level of Aβ-induced DSBs. Their neuroprotective effect was as efficient as RA in most cases, with the exception of vitamin C that was consistently less efficient. Moreover, additive or synergetic effects between RA and glutathione, α-tocopherol, or L-carnitine to reduce DSBs were not observed. There was even an increase of DSBs in the case of the combined treatment of vitamin C and RA. Thus, our observations suggest that overall neuroprotection against Aβ-induced DSBs is implemented by several pathways acting independently. The diminution of these compounds with age might increase the general tissular vulnerability and DSB occurrence. Antioxidants, such as vitamin C and α-tocopherol, are indeed known to diminish in the blood of AD patients and patients with Mild Cognitive Impairment [40]. However, to ascertain this conclusion, these experiments should be repeated in combination with other vitamins and RA and with young and old mice.

4.3. Retinoic Acid Decreases the Amyloid Cascade in Young and Aged Cortical Tissues. RA was shown to increase in a short time the expression of ADAM10/α-secretase, an enzyme known to counteract the amyloid cascade by cleaving the Aβ sequence of the APP protein [32, 41]. However, we suggest here that ADAM10 is implicated in RA neuroprotection against Aβ-induced DSBs, especially as the Presenilin-1 protein, corresponding in our experiments to the immature uncleaved form [42], and the BACE1 protein did not show an increase in expression. Furthermore, it was already shown that RA inhibits the γ-secretase, thus increasing APP [34]. Note that the increase of the 110 kDa APP signal suggests that, despite increased cleavage at the α-site, there is an enhanced APP expression due to the activated RA-dependent metabolism. Increased expression of APP in the hippocampus and various cell lines was already observed [43]. Overall, the RA treatment appears to favor the antiamyloidogenic pathway and thus a decreased production of Aβ.

The fact that the increase of ADAM10 and APP expressions reached statistical significance only in the deep cortical layers of young mice might be related to the preferential vulnerability of the superficial neocortical layers to the Aβ treatment [44, 45] and to the preferential presence in these layers of amyloid plaques [46, 47]. Significantly increased unphosphorylated as well as phosphorylated Tau signals in the deep cortical layers only, subsequent to the RA treatment, suggests an activation of the metabolism in these layers mainly, contributing possibly to their increased resistance to Aβ.

The increased expression of PSD-95 due to RA is already known [48, 49]. In this study, we showed increased RA-dependent expressions of PSD-95 and GluN2B. However, they did not reach levels of significance due to the small numbers of samples (n = 3).

Particularly interesting was the fact that the RARα and PPARβ/δ receptors were not increased in expression following the RA treatment, if we except the PPARβ/δ receptor in the deep cortical layers. Thus, the effects of the corresponding pathways on the proteins of the amyloid cascade and on the Tau protein might occur, if not by transcription, through nongenomic effects. However, it is possible that other RA-dependent receptors, such as RARβ [50], are involved at the transcriptional level. Note that the higher expression of the RARα and PPARβ/δ receptors with age and in the superficial cortical layers might be related to a neuroprotective role.

4.4. Aβ-Induced DSBs Need Transcription and Translation Whereas RA-Dependent Neuroprotection against Aβ-Induced DSBs Occurs through Posttranslational Mechanisms. We showed that RA was decreasing DSBs when transcription was inhibited for 30 min, 2 × 30 min, or 1 h. As RA was shown not to enhance RARα or PPARβ/δ expression in most of the murine brain tissues studied, we can propose that RA acts at the posttranslational level by favoring receptor dimerization with RXRs, chromosome decondensation, and DSB repair or prevention. Transcription of various gene products such as ADAM10 of the antiamyloidogenic cascade (Figure 3), BRCA1 [6], or antioxidant gene products, all involved in some way in DSB prevention or repair, would also be initiated but with delayed effects. The PPARβ/δ activation might also increase the expression of neprilysin or insulin-degrading enzyme [51], thus decreasing the Aβ content and DSBs. The fast, non-transcription-dependent DSB prevention and repair
4.5. Neuroprotection against Aβ-Induced DSBs Is Mediated by Both the RARα/β/γ and PPARβ/δ Pathways. We demonstrated that RA in the presence of RARα/β/γ and PPARβ/δ antagonists can protect against Aβ-induced DSBs, not only via RAR receptors but also via the PPARβ/δ receptor. 9-cis RA was used as comparison. The inhibition of both RARα/β/γ and PPARβ/δ receptors with either AGN or GSK in the presence of Aβ and RA resulted in the same level of Aβ-induced DSBs as the Aβ control treatment, suggesting that in the SH-SY5Y cells, these pathways are the major ones, if not the only ones.

The PLA experiments showed a significant increase of PPARβ/δ-RXRα/β/γ heterodimers, not of RARα-RXRα/β/γ heterodimers, following a double-step RA-Aβ treatment. Significance was reached in the cell cytoplasm, and only a tendency was observed for the cell nucleus. The increase of PPAR was corroborated by immunocytochemistry. This suggests that RA increases PPAR in the cytoplasm and possibly in the cell nucleus, favoring interactions with RXR and the protection against Aβ-induced DSBs. In the absence of Aβ, the increased heterodimerization was not observed. Thus, it appears that, under the specific conditions used, whereas the RAR pathway is not, no more, or not yet active, the PPAR pathway is activated or still actively promoting attempts of cell division and antiapoptotic conditions [35].

5. Conclusions

Overall, our data suggest that the Aβ-induced DSBs can be prevented by RARα/β/γ or PPARβ/δ receptors after their shuffling in the cell nucleus in the presence of RA. In the longer term, this could also result in tilting the balance of gene expression in favor of the antiamyloidogenic pathway, via ADAM10 increased expression, thus reducing Aβ generation. We proposed previously [27] that RA is involved in the repair of Aβ-induced DSBs. We have now shown that this phenomenon appears to be complemented by RA-dependent neuroprotection. Furthermore, it is possible that, depending on the distribution and levels of RA (and other vitamins) and on the Aβ production in the aging brain, a mosaic of Aβ-induced DSBs would result and only a subset of functionally important genes, such as RA-dependent genes, would be selectively protected and not other age dispensable genes. Such targeted prevention of DSBs by Adaptive Gene Expression (DSB-AGE hypothesis) would allow maintenance in an energy economical manner of genes of at least the most important survival brain functions, such as memory. In all cases, this study corroborates the observations suggesting that the RA pathways can be targets of preventive strategies.

Data Availability

All data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no actual or potential conflict of interest.

Authors’ Contributions

Julien Colas and Natacha Chessel contributed equally to this work.

Acknowledgments

We thank Françoise Piotton and Marcella M. Authiat for technical assistance. Financial and material support was institutional (University Hospital of Geneva).

References

[1] V. Theendakara, C. A. Peters-Libeu, P. Spilman, K. S. Poksay, D. E. Breidesen, and R. V. Rao, “Direct transcriptional effects of apolipoprotein E,” *The Journal of Neuroscience*, vol. 36, no. 3, pp. 685–700, 2016.

[2] G. Multhaup, O. Huber, L. Buee, and M. C. Galas, “Amyloid precursor protein (APP) metabolites APP intracellular fragment (AICD), Aβ42, and tau in nuclear roles,” *The Journal of Biological Chemistry*, vol. 290, no. 39, pp. 23515–23522, 2015.

[3] C. Barucker, A. Hamermeier, J. Weiske et al., “Nuclear translocation uncovers the amyloid peptide Aβ42 as a regulator of gene transcription,” *The Journal of Biological Chemistry*, vol. 289, no. 29, pp. 20182–20191, 2014.

[4] C. Barucker, A. Sommer, G. Beckmann et al., “Alzheimer amyloid peptide Aβ42 regulates gene expression of transcription and growth factors,” *Journal of Alzheimer’s Disease*, vol. 29, no. 2, pp. 613–624, 2015.

[5] L. N. Zhao, J. Zheng, L. Y. Chew, and Y. Mu, “An investigation on the fundamental interaction between Abeta peptides and the AT-rich DNA,” *The Journal of Physical Chemistry B*, vol. 119, no. 26, pp. 8247–8259, 2015.

[6] E. Suberbielle, P. E. Sanchez, A. V. Kravitz et al., “Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β,” *Nature Neuroscience*, vol. 16, no. 5, pp. 613–621, 2013.

[7] M. F. Wu, J. H. Yin, C. S. Hwang, C. M. Tang, and D. I. Yang, “NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons,” *Free Radical Research*, vol. 48, no. 7, pp. 794–805, 2014.

[8] M. A. Lovell and W. R. Markesbery, “Oxidative damage in mild cognitive impairment and early Alzheimer’s disease,” *Journal of Neuroscience Research*, vol. 85, no. 14, pp. 3036–3040, 2007.

[9] E. Suberbielle, B. Djukic, M. Evans et al., “DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice,” *Nature Communications*, vol. 6, no. 1, article 8897, 2015.

[10] A. Cardinale, M. Racaniello, S. Saladini et al., “Sublethal doses of β-Amyloid peptide abrogate DNA-dependent protein
kinase activity,” The Journal of Biological Chemistry, vol. 287, no. 4, pp. 2618–2631, 2012.

[11] D. A. Shackelford, “DNA end joining activity is reduced in Alzheimer’s disease,” Neurobiology of Aging, vol. 27, no. 4, pp. 596–605, 2006.

[12] C. Culmsee, S. Bondada, and M. P. Mattson, “Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity,” Brain Research Molecular Brain Research, vol. 87, no. 2, pp. 257–262, 2001.

[13] R. Madabhushi, F. Gao, A. R. Pfennig et al., “Activity-induced DNA breaks govern the expression of neuronal early-response genes,” Cell, vol. 161, no. 7, pp. 1592–1605, 2015.

[14] C. Orlowski, L. J. Mah, R. S. Vasireddy, A. El-Osta, and T. C. Karagiannis, “Double-strand breaks and the concept of short- and long-term epigenetic memory,” Chromosoma, vol. 120, no. 2, pp. 129–149, 2011.

[15] U. Swain and K. Subba Rao, “Study of DNA damage via the comet assay and base excision repair activities in rat brain neurons and astrocytes during aging,” Mechanisms of Ageing and Development, vol. 132, no. 8–9, pp. 374–381, 2011.

[16] R. Madabhushi, L. Pan, and L. H. Tsai, “DNA damage and its links to neurodegeneration,” Neuron, vol. 83, no. 2, pp. 266–282, 2014.

[17] R. R. White, B. Milholland, A. de Bruin et al., “Controlled induction of DNA double-strand breaks in the mouse liver induces features of tissue aging,” Nature Communications, vol. 6, no. 1, article 6790, 2015.

[18] F. Coppede and L. Migliore, “Evidence linking genetics, environment, and epigenetics to impaired DNA repair in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 20, no. 4, pp. 953–966, 2010.

[19] E. Adamiec, J. P. Vonsattel, and R. A. Nixon, “DNA strand breaks in Alzheimer’s disease,” Brain Research, vol. 849, no. 1-2, pp. 67–77, 1999.

[20] N. H. Myung, X. Zhu, I. I. Kruman et al., “Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes,” Age, vol. 30, no. 4, pp. 209–215, 2008.

[21] E. Mullaart, M. E. Boerrigter, R. Ravid, D. F. Swaab, and J. Vijg, “Increased levels of DNA breaks in cerebral cortex of Alzheimer’s disease patients,” Neurobiology of Aging, vol. 11, no. 3, pp. 169–173, 1990.

[22] F. Coppede and L. Migliore, “DNA damage in neurodegenerative diseases,” Mutation Research, vol. 776, pp. 84–97, 2015.

[23] D. Merlo, C. Mollinari, M. Racanelli, E. Garaci, and A. Cardinale, “DNA double strand breaks: a common theme in neurodegenerative diseases,” Current Alzheimer Research, vol. 13, no. 11, pp. 1208–1218, 2016.

[24] J. Chen and K. Herrup, “Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress,” PLoS One, vol. 7, no. 3, article e33177, 2012.

[25] M. Violet, L. Delatte, M. Tardivel et al., “A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions,” Frontiers in Cellular Neuroscience, vol. 8, p. 84, 2014.

[26] M. Violet, A. Chauderlier, L. Delatte et al., “Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo,” Neurobiology of Disease, vol. 82, pp. 540–551, 2015.

[27] E. Gruz-Gibelli, N. Chesel, C. Allioux et al., “The Vitamin A derivative all-trans retinoic acid repairs amyloid-β-induced double-strand breaks in neural cells and in the murine neocortex,” Neural Plasticity, vol. 2016, Article ID 3707406, 11 pages, 2016.

[28] K. D. Shearer, P. N. Stoney, P. J. Morgan, and P. J. McCaffrey, “A vitamin for the brain,” Trends in Neurosciences, vol. 35, no. 12, pp. 733–741, 2012.

[29] N. Etchamendy, V. Enderlin, A. Marighetto et al., “Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling,” The Journal of Neuroscience, vol. 21, no. 16, pp. 6423–6429, 2001.

[30] Y. Ding, A. Qiao, Z. Wang et al., “Retinoic acid attenuates β-amylloid deposition and rescues memory deficits in an Alzheimer’s disease transgenic mouse model,” The Journal of Neuroscience, vol. 28, no. 45, pp. 11622–11634, 2008.

[31] R. K. Sodhi and N. Singh, “Retinoids as potential targets for Alzheimer’s disease,” Pharmacology, Biochemistry, and Behavior, vol. 120, pp. 117–123, 2014.

[32] C. I. Jarvis, M. B. Goncalves, E. Clarke et al., “Retinoic acid receptor-α signalling antagonizes both intracellular and extracellular amyloid-β production and prevents neuronal cell death caused by amyloid-β,” The European Journal of Neuroscience, vol. 32, no. 8, pp. 1246–1255, 2010.

[33] S. Holback, L. Adlerz, T. Gatsinzi, K. T. Jacobsen, and K. Iverfeldt, “PI3-K- and PKC-dependent up-regulation of APP processing enzymes by retinoic acid,” Biochemical and Biophysical Research Communications, vol. 365, no. 2, pp. 298–303, 2008.

[34] A. Kapoor, B. J. Wang, W. M. Hsu, M. Y. Chang, S. M. Liang, and Y. F. Liao, “Retinoic acid-elicted RARα/RXRα signaling attenuates Aβ production by directly inhibiting γ-secretase-mediated cleavage of amyloid precursor protein,” ACS Chemical Neuroscience, vol. 4, no. 7, pp. 1093–1100, 2013.

[35] N. Noy, “Between death and survival: retinoic acid in regulation of apoptosis,” Annual Review of Nutrition, vol. 20, pp. 201–217, 2010.

[36] J. M. Zolezzi and N. C. Inestrosa, “Peroxisome proliferator-activated receptors and Alzheimer’s disease: hitting the blood-brain barrier,” Molecular Neurobiology, vol. 48, no. 3, pp. 438–451, 2013.

[37] E. H. Radany, M. Brenner, F. Besnard, V. Bigornia, J. M. Bishop, and C. F. Deschepper, “Directed establishment of rat brain cell lines with the phenotypic characteristics of type 1 astrocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 14, pp. 6467–6471, 1992.

[38] L. Pellerin, M. Stolz, O. Sorg, J. L. Martin, C. F. Deschepper, and P. J. Magistretti, “Regulation of energy metabolism by neurotransmitters in astrocytes in primary culture and in an immortalized cell line,” Glia, vol. 21, no. 1, pp. 74–83, 1997.

[39] L. Eder-Colli, N. Abad-Estarlich, C. Pannetier et al., “The presenilin-1 familial Alzheimer’s disease mutation P117L decreases neuronal differentiation of embryonic murine neural progenitor cells,” Brain Research Bulletin, vol. 80, no. 4-5, pp. 296–301, 2009.

[40] M. Schrag, C. Mueller, M. Zabel et al., “Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a meta-analysis,” Neurobiology of Disease, vol. 59, pp. 100–110, 2013.

[41] P. Saftig and S. F. Lichtenthaler, “The alpha secretase ADAM10: a metallopeptase with multiple functions in the brain,” Progress in Neurobiology, vol. 135, pp. 1–20, 2015.
[42] B. De Strooper, M. Beullens, B. Contreras et al., “Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer’s disease-associated presenilins,” *Journal of Biological Chemistry*, vol. 272, no. 6, pp. 3590–3598, 1997.

[43] M. A. Lane and S. J. Bailey, ”Role of retinoid signalling in the adult brain,” *Progress in Neurobiology*, vol. 75, no. 4, pp. 275–293, 2005.

[44] R. R. Romito-DiGiacomo, H. Menegay, S. A. Cicero, and K. Herrup, ”Effects of Alzheimer’s disease on different cortical layers: the role of intrinsic differences in Aβ susceptibility,” *The Journal of Neuroscience*, vol. 27, no. 32, pp. 8496–8504, 2007.

[45] P. Fugistier, P. G. Vallet, G. Leuba et al., “Comparison of frailty of primary neurons, embryonic, and aging mouse cortical layers,” *Neurobiology of Aging*, vol. 35, no. 2, pp. 322–330, 2014.

[46] C. Duyckaerts, J. J. Hauw, F. Bastenaire et al., ”Laminar distribution of neocortical senile plaques in senile dementia of the Alzheimer type,” *Acta Neuropathologica*, vol. 70, no. 3-4, pp. 249–256, 1986.

[47] J. H. Morrison and P. R. Hof, ”Life and death of neurons in the aging brain,” *Science*, vol. 278, no. 5337, pp. 412–419, 1997.

[48] N. Chen and J. L. Napoli, ”All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARα,” *The FASEB Journal*, vol. 22, no. 1, pp. 236–245, 2008.

[49] D. Bonhomme, V. Pallet, G. Dominguez et al., ”Retinoic acid modulates intrahippocampal levels of corticosterone in middle-aged mice: consequences on hippocampal plasticity and contextual memory,” *Frontiers in Aging Neuroscience*, vol. 6, p. 6, 2014.

[50] F. Tippmann, J. Hundt, A. Schneider, K. Endres, and F. Fahrenholz, ”Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin,” *The FASEB Journal*, vol. 23, no. 6, pp. 1643–1654, 2009.

[51] S. Kalinin, J. C. Richardson, and D. L. Feinstein, ”A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease,” *Current Alzheimer Research*, vol. 6, no. 5, pp. 431–437, 2009.